5 Healthcare Stocks in Focus

Pfizer Inc. (NYSE: PFE) today announced the phase 3 results of investigational
compound bosutinib in patients with newly diagnosed chronic myeloid leukemia.
The study had a significantly higher proportion of patients with newly diagnosed
chronic myeloid leukemia who were treated with bosutinib (39 percent)
experienced a major molecular response (MMR), a secondary endpoint, compared
with patients treated with imatinib (26 percent) in the intent-to-treat (ITT)
population (p=0.002). The study did not meet its primary endpoint of superior
complete cytogenetic response (CCyR) rate at one year versus imatinib (70
percent vs. 68 percent, respectively, [p=0.601]), in the ITT population. Pfizer
holds diversified global health care portfolio including human and animal
biologic and small molecule medicines and vaccines, as well as nutritional
products and many consumer health care products. Eli Lilly & Co. (NYSE: LLY)
announced in association with Acrux received the FDA approval for breakthrough
testosterone drug, Axiron. The Axiron is a  topical solution CIII for
testosterone replacement therapy in men. The Axiron is the first testosterone
topical solution approved for application via an underarm applicator. This
announcement came after Lilly acquired the global licensing rights to Axiron
from Acrux for $335 million plus royalties. Eli Lilly is involved in discovery,
development, manufacturing and selling pharmaceutical products. Johnson &
Johnson (NYSE: JNJ) announced that Janssen Pharmaceutical companies of Johnson &
Johnson has a research agreement to collaborate with GE Healthcare to develop
non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimers
disease prior to the onset of clinical symptoms. The pre-symptomatic
biosignatures allows earlier diagnosis of the disease and may enable
significantly earlier intervention in Alzheimers disease. Johnson & Johnson
engages in the research and development, manufacture and sale of a range of
products in the health care field. GlaxoSmithKline plc (ADR) (NYSE: GSK) in
association with Valeant Pharmaceuticals International announced receipt of a
complete response letter from the U.S. FDA for the New Drug Application for
ezogabine, an investigational anti-epileptic drug being studied for the
adjunctive treatment of adults with partial-onset seizures. GlaxoSmithKline
engages in the creation and discovery, development, manufacture and marketing of
pharmaceutical products, including vaccines, over-the-counter medicines and
health-related consumer products. Amgen Inc. (NASDAQ:  AMGN) yesterday
announced final results from its 5-year open-label extension study investigating
the long-term efficacy and safety of Nplate in adults with chronic immune
thrombocytopenic purpura. The Nplate safely and effectively maintained platelet
counts in the significant majority of patients for the duration of the study.
Amgen is involved in the discovery, development, manufacturing and marketing of
medicines for grievous illnesses. It focuses on human therapeutics and
concentrates on medicines based on advances in cellular and molecular biology.